研究人员表示，虽然距离临床应用还有很长的路，但这项技术已经展现出巨大潜力。想象一下，未来医 生或许能像修复电路一样，精准修复出问题的大脑连接，而不会伤及健康脑区。 美国南加州大学研究团队开发出两款"黑科技"，其能像开关一样选择性且可逆地断开脑细胞之间的连 接。这一成果发表于新一期《eLife》杂志，有望改变脑科学研究，并为治疗癫痫、成瘾和创伤后应激 障碍等神经系统疾病开辟新途径。 （文章来源：科技日报） 团队还开发了两种可按需激活的GFE3工具：一种通过光激活（paGFE3），另一种通过化学信号激活 （chGFE3）。他们表示，借助这些工具，科学家能精准"剪断"特定神经连接，还能让它们重新长回 来。整个过程就像外科手术般精确，只针对目标突触，其他脑细胞完全不受影响。这种可逆、精准的操 作方式，让科学家能更深入地研究记忆、情绪、行为背后的神经机制。 在研究中，该团队从大脑自带的"回收系统"获得灵感，开发出两种分子工具：靶向兴奋性突触（让神经 连接更活跃的突触）的PFE3和靶向抑制性突触（让神经连接更少的突触）的GFE3。突触是神经元之间 在功能上发生联系的部位，也是信息传递的关键部位。 研究人员解释说，在大脑内 ...

Group 1 - At least five Chinese companies plan to conduct IPOs, dual listings, or placements in Singapore within the next 12 to 18 months, indicating a trend of Chinese firms seeking to diversify their capital sources in Southeast Asia [1] - The companies planning to list in Singapore span various industries, including an energy company, a medical group, and a Shanghai-based biotechnology firm [1] - Some companies may aim to raise approximately $100 million through listings on the Singapore mainboard [1] Group 2 - This trend is expected to boost the performance of the Singapore Exchange (SGX), which has struggled to attract large listings and increase trading volume [2] - In 2024, the SGX has only recorded four IPOs, and it is not typically the first choice for Chinese companies looking to list overseas, with Hong Kong being more favored [2] - To enhance market attractiveness, Singapore has introduced a series of revitalization measures for the stock market, including tax incentives and simplified listing processes [2] Group 3 - Observers note that Singapore's local investors are relatively conservative, and the stricter listing requirements may hinder the exchange's ability to close the gap with Hong Kong in the short term [2] - Singapore is recognized as a world-class financial center with mature legal and regulatory frameworks, which can be appealing to Chinese companies [2] - Companies need to be aware of market risks, regulatory differences, and valuation recognition when considering listings in Singapore [2]

截至目前，温江区科学技术局已累计帮助区内企业获得"科创贷"27亿元，助力570余家科技企业成长为 国家高新技术企业。 "下一步，我们将常态化举办'创投天府'等政银企对接活动。同时，加快推进财政科技资金'先投后股'改 革试点，提升'投新、投早、投小、投硬'能力，构建'债权+股权+基金'多元联动、接续发力的金融服务 生态，全方位赋能科创企业发展壮大。"温江区科学技术局相关负责人表示。 活动中还进行了多轮签约，中国农业银行成都分行、成都生产力促进中心、温江区科学技术局共同签 署"科创贷"三方合作协议，成都海峡中小企业孵化园等温江区产业载体、健诺维（成都）生物科技有限 公司等温江区企业纷纷与金融机构达成合作或签署投融资意向协议。 近年来，温江区科学技术局紧扣科技型企业需求，从出台科技创新若干政策、培育科技金融服务机构、 搭建投融资对接平台、大力推广"科创贷"等多个维度同时发力，切实解决科技型企业资金难题。去年， 在全省率先探索财政科技资金"先投后股"改革试点，并建立2000万元风险资金池，通过杠杆效应带动农 业银行和成都银行（601838）两家合作银行安排2.5亿元贷款资金用于"科创贷"业务，满足科技型中小 企业日益 ...

Group 1: Industry Performance - The healthcare ETF rose by 2.02%, while the biotechnology index ETF increased by 1.61% [1][3] - The global airline industry ETF saw a gain of 1.07%, and the consumer discretionary ETF rose by 0.95% [1][3] - The technology sector ETF and banking sector ETF had minimal increases, with gains of up to 0.19% [1][3] Group 2: ETF Specifics - The healthcare ETF closed at $133.09, with a change of +2.63 (+2.02%) and a total market value of $254.69 billion, down 2.88% year-to-date [3] - The biotechnology index ETF closed at $121.16, with a change of +1.92 (+1.61%) and a total market value of $96.20 billion, down 8.28% year-to-date [3] - The global airline ETF closed at $22.74, with a change of +0.24 (+1.07%) and a total market value of $716.31 million, down 10.30% year-to-date [3] Group 3: Sector Trends - The energy sector ETF decreased by 0.15%, while the semiconductor ETF fell by 0.29% [2][3] - The utilities sector ETF increased by 1.47%, closing at $82.18, with a total market value of $119.30 billion, up 9.35% year-to-date [3] - The consumer staples ETF rose by 1.15%, closing at $82.07, with a total market value of $138.88 billion, up 4.95% year-to-date [3]

Group 1 - The core index, the CESHKB, increased by 1.98% to 5775.66 points, with a trading volume of 6.408 billion [1] - Over the past month, the CESHKB has risen by 7.34%, by 17.05% over the last three months, and by 28.90% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, set at 2000.0 points [1] Group 2 - The top ten holdings of the CESHKB include: Innovent Biologics (10.8%), CanSino Biologics (10.42%), WuXi Biologics (10.27%), China National Pharmaceutical Group (9.64%), BeiGene (9.22%), Kelun-Biotech (5.32%), Zai Lab (5.26%), WuXi AppTec (5.16%), 3SBio (5.15%), and Genscript Biotech (3.23%) [1] - The CESHKB is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% representation [2] - The industry representation of the CESHKB is entirely in the healthcare sector, specifically pharmaceuticals and biotechnology, also at 100% [2]

Core Viewpoint - The U.S. stock market opened with mixed performance among major industry ETFs, with healthcare and biotechnology ETFs rising nearly 1%, while energy ETFs fell close to 1% [1] Industry Summary - **Healthcare ETF**: Current price at $131.42, increased by $0.96 (+0.74%), with a trading volume of 1.58 million shares and a total market value of $25.15 billion, down 4.10% year-to-date [2] - **Biotechnology Index ETF**: Current price at $120.06, up by $0.82 (+0.69%), with a trading volume of 99,650 shares and a total market value of $9.53 billion, down 9.11% year-to-date [2] - **Energy ETF**: Current price at $85.01, decreased by $0.60 (-0.70%), with a trading volume of 1.36 million shares and a total market value of $21.29 billion, up 0.02% year-to-date [2] - **Global Airline ETF**: Current price at $22.61, increased by $0.10 (+0.47%), with a trading volume of 121,200 shares and a total market value of $712.06 million, down 10.83% year-to-date [2] - **Technology Sector ETF**: Current price at $234.00, decreased by $0.45 (-0.19%), with a trading volume of 604,400 shares and a total market value of $74.43 billion, up 0.81% year-to-date [2] - **Financial Sector ETF**: Current price at $51.30, increased by $0.02 (+0.04%), with a trading volume of 3.65 million shares and a total market value of $57.10 billion, up 6.53% year-to-date [2]

Core Insights - The "Investment Cooperation Exchange Conference" held in Chengdu aims to connect enterprises with financing institutions, promoting deep integration of capital and industry, with over 30 billion yuan in financing needs announced [1][5][12] Group 1: Investment Advantages of Deyang - Deyang is positioned as a key node in the Chengdu-Chongqing economic circle, benefiting from strategic national and provincial policies, and enjoys a location advantage of "Chengdu quality, Deyang cost" [3] - The city has a strong manufacturing base, being a national hub for major technical equipment manufacturing, producing 60% of the country's nuclear power units and 50% of large castings [3] - Deyang boasts robust technological innovation, with significant R&D investment and 25 national-level specialized "little giant" enterprises [3] - The cost of factors such as industrial land and logistics is 30% lower than in eastern regions, potentially increasing corporate net profits by 5 percentage points [3] - Deyang has a highly efficient business environment, ranking in the top three in the province for five consecutive years, with streamlined processes for business operations [3] Group 2: Financing Needs and Opportunities - The Deyang Investment Control Group presented a fund matrix showcasing financing needs from 50 local enterprises, totaling over 30 billion yuan, covering high-growth sectors like advanced equipment, new energy, and biotechnology [5] - Notable financing requests include 600 million yuan from Bohai New Energy and over 100 million yuan from Deyang Keji High-tech Materials and Sichuan Hongda, with small and micro enterprises seeking between 5 million to 200 million yuan [5] Group 3: Capital and Industry Integration - The conference attracted over 50 well-known investment institutions, facilitating direct communication between Deyang enterprises and potential investors [7][12] - The Deyang Economic Cooperation Bureau established a financing communication platform to foster connections between venture capital institutions and local businesses, with seven institutions planning site visits to Deyang [12] Group 4: Future Development Goals - Deyang aims to build the "China Equipment Technology City" and accelerate the establishment of a modern industrial system, signaling openness to national venture capital institutions [14] - The city plans to deepen cooperation among government, finance, and enterprises, creating a win-win ecosystem to support high-quality development in the Chengdu-Chongqing economic circle [14]

Group 1 - The Hang Seng Biotechnology Index will include companies Same Origin Health (02410.HK) and Kangji Medical (09997.HK) [1] - The index will exclude companies CStone Pharmaceuticals-B (09966.HK) and Rongchang Biopharmaceuticals (09995.HK) [1]

Core Insights - Shenzhen Lingzhu Technology Co., Ltd. has completed several million yuan in angel round financing from Shenzhen Innovation Investment Group, marking a significant milestone in the mass production of recombinant spider silk protein and the establishment of a pilot production base [2] - The company has developed a unique full-length spider silk gene library, enabling the production of differentiated fiber materials with a production cost reduction of over 60% and an annual capacity reaching hundreds of tons [2] Group 1: Company Overview - Lingzhu Technology was founded in 2019 and is headquartered in Shenzhen, co-founded by Wang Boxiang and Liang Qing, utilizing microbial fermentation and silkworm technology for efficient mass production of spider silk protein fibers [5] - The core team consists of experts in bioengineering, materials science, and AI algorithms, with the financing round aimed at capacity expansion, technology research and development, and market expansion [5] Group 2: Product and Technology - The recombinant spider silk protein fibers have received recognition from multiple brands and institutions, indicating strong market validation [4] - Lingzhu has established collaborations with several well-known companies and universities, including Tianjin University of Technology and Hong Kong Polytechnic University, to further innovate and apply spider silk technology [4]

美国总统特朗普的对华"围剿战"非但没有取得预期的效果，反而还把美国自身的经济越高越差，特朗普的 支持率也逐渐走低，甚至威胁到自身的政权稳固。特朗普的这一招反华牌究竟错在哪？东方大国和美国在 瑞士的谈判刚刚告一段落。从两国发表的声明来看，美国决定将对华关税降到合理区间，东方大国也表 示，对美国的反制举措将慎重考虑。相比四月初到现在，特朗普对华一路飙升的关税税率，此番与东方大 国的谈判，美国还是低头了。 事实上，从第一任任期，到第二任任期，特朗普就从各方面对东方大国形成围堵。在关税上，特朗普在第 一任任期，突然对东方大国的高科技产品加收关税。在台海问题上，特朗普大打台湾牌，向台湾输送大量 军事武器，伙同台湾当局，就台海问题向东方大国挑衅。在南海问题上，特朗普则拉拢菲律宾，持续就南 海主权问题，展开军事演习，向菲律宾输送导弹，威胁东方大国安全。在科技问题上，特朗普则把一众科 技公司纳入所谓实体清单，威胁荷兰、日本等国，以及台湾，不再向东方大国提供芯片，一度让东方大国 的科技企业出现缺芯少片的状况。 特朗普（资料图） 贝森特（资料图） 不仅如此，在台海问题、南海问题、中日关系上，特朗普派出得力干将，不断开展军事演习， ...